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Summary Gemcitabine is a deoxycytidine (dCyd) analog
with activity in leukemia and solid tumors, which requires
phosphorylation by deoxycytidine kinase (dCK). Decreased
membrane transport is a mechanism of resistance to
gemcitabine. In order to facilitate gemcitabine uptake and
prolong retention in the cell, a lipophilic pro-drug was
synthesized (CP-4126), with an elaidic fatty acid esterified
at the 5′position. CP-4126 was tested in cell lines resistant
to cytarabine, another dCyd analog or gemcitabine. Activity
of gemcitabine and the derivative was comparable in the
parent cell lines, while in dCK deficient cells all com-
pounds were inactive. However, inhibition of nucleoside
transport increased the IC50 for gemcitabine up to 200-fold,
but not for CP-4126, underlining the independence of a
nucleoside transporter. For in vivo evaluation, nude mice
bearing a human xenograft were treated intraperitoneally
every third day for five doses at the maximal tolerated dose.
In melanoma, sarcoma, lung, prostate, pancreatic and breast
cancer xenografts, gemcitabine and CP-4126 were equally
and highly effective; in four other xenografts moderately
but equally active. In contrast to gemcitabine, CP-4126 could
be administered orally, with a schedule and dose dependent
toxicity and antitumor activity. In a colon cancer xenograft,
antitumor activity of orally administered CP-4126 was equal
to the intraperitoneally administered drug. In conclusion, CP-
4126 is membrane transporter independent. Intraperitoneally
administered CP-4126 was as effective as gemcitabine in
several xenografts and CP-4126 is tolerated when orally
administered. CP-4126 seems to be a promising new
anticancer drug.
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Introduction
Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is a dCyd
analog, which is active against several types of solid
tumors, including Non-Small Cell Lung Cancer (NSCLC)
and pancreatic carcinoma [1–4]. Gemcitabine requires
phosphorylation by deoxycytidine kinase (dCK) in order
to be active, and can be inactivated by deamination by
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deoxycytidine deaminase (dCDA) to 2′,2′-difluorodeoxyur-
idine (dFdU) [5]. After conversion by kinases to its active
form, 2′,2′-difluorodeoxycytidine triphosphate (dFdCTP), it
can be incorporated into DNA and is a potent inhibitor of
DNA-synthesis by inhibition of DNA polymerase [6, 7].
Moreover, gemcitabine, as dFdCTP, is also incorporated
into RNA [8].
The inherent or acquired resistance of tumors to cytostatic
agents is a major clinical problem. Like other nucleoside
analogs, gemcitabine is hydrophilic and cannot traverse cell
membranes by passive diffusion [9]. Specialized transport
systems are required for the passage of nucleoside analogs
in or out of the cell [10]. Altered nucleoside transport
activity as a mechanism of drug resistance has been
described for gemcitabine and the structurally and func-
tionally related cytarabine (ara-C) [11, 12].
Since decreased sensitivity to gemcitabine might be
the result of reduced drug accumulation, a fatty acid
ester derivative of gemcitabine CP-4126 was synthesized
(Fig. 1a). The derivative was intended to facilitate the
increased accumulation and retention of gemcitabine in
the tumor cells. A similarly esterified cytarabine deriva-
tive, CP-4055, appeared to be one of the most promising
lipophilic cytarabine pro-drugs, which enhanced retention
of the drug effects [13, 14]. This drug now has shown
acceptable tolerability in phase I studies [15] and is currently
tested in phase II studies on solid tumors and leukemia. In
CP-4126, the elaidic acid (trans-9-octadecenoic fatty acid)
was coupled to the 5′ position on the sugar moiety. In the
cell, CP-4126 needs to be converted to gemcitabine by
esterases in order to be phosphorylated. In this paper we
describe cytotoxicity of CP-4126 in cytarabine and gemci-
tabine sensitive and resistant cell lines, independency of
membrane transport systems, the modulation of dCDA
activity and its in vivo activity against human tumor
xenografts when administered both intraperitoneally (ip)
and orally.
Materials and methods
Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) and RPMI-
1640 were purchased from Flow Laboratories (Irvine, UK)
and fetal calf serum (FCS) from Gibco (New York, USA),
Rat serum was purchased from Harlan/Olac (Zeist, the
Netherlands), trichloroacetic acid (TCA), glutamine and
gentamycin from Merck (Darmstadt, Germany), trypsin,
sulforhodamine B (SRB), NBMPR and dipyridamole from
Sigma-Aldrich (St. Louis, MO, USA). Gemcitabine was
obtained from the local pharmacy department. CP-4126
was provided by Clavis Pharma (Oslo, Norway). [2-14C]-
TdR, 62.8 mCi/mmol was purchased from Dupont de
Nemours NEND (Dreiech, Germany) and [5-3H]-UR,
27.0 Ci/mmol from Amersham (Buckinghamshire, UK)
and propanidid from Sombrevin; Gedeon Richter Ltd.
(Budapest, Hungary). All other chemicals were of analyt-
ical grade and commercially available.
Preparation of the test samples
CP-4126 was dissolved in DMSO to a final concentration of
20 mM. Serial dilutions ranging from 8.10−10M to 10−3M
were prepared of the stock solution in cell culture medium.
Drug concentrations >10−3M could not be obtained due to
precipitation of the compound in the wells. Moreover, at a
concentration of 2.10−3M cells would be exposed to a toxic
concentration of DMSO (>1%); therefore concentrations
were chosen in a range that would never expose cells to
more than 1% DMSO. The stock solutions of gemcitabine
and CP-4126 were stored at −20°C. CP-4126 for animal
experiments was supplied as a ready to use, sterile, colloidal
suspension, stored at 2–8°C.
Cell culture
The in vitro experiments were performed in cell lines of
leukemic and solid tumor origin, both sensitive and
resistant to gemcitabine. Murine leukemia L1210 cells,
used as its variant L5, and the cytarabine resistant variant
L4A6 were routinely cultured in suspension in RPMI-1640
medium supplemented with 10% fetal calf serum (FCS),
60 μM 2-β-mercaptoethanol and 250 ng/ml gentamicin, as
described previously [16]. Rat leukemia BCLO cells were
cultured in RPMI-1640 medium, as described [17], supple-
mented with 3.2 mM L-glutamine, 10% FCS and 250 ng/ml
gentamicin, the cytarabine resistant variant Bara-C was
cultured in the same medium as BCLO, but instead of 10%
FCS, supplemented with 5% FCS and 5% rat serum. BCLO
and Bara-C were generously provided by Dr L. Colly (then
at Dept. Hematology, University Hospital Leiden, the
Netherlands). The solid tumor cell lines were A2780, a
human ovarian cancer cell line [18] and its variant AG6000,
which is highly resistant to gemcitabine [19]. The murine
colon cancer cell lines C26-A and C26-G were derived
from the murine Colon 26-A tumor and its variant Colon
26-G with an in vivo induced resistance to gemcitabine,
respectively [20]. The resistance was related to over-
expression of ribonucleotide reductase subunit M1
(RRM1) RNA [21]. These and the other solid tumor cell
lines were grown as monolayers in DMEM supplemented
with 5% FCS, and 250 ng/ml gentamicin. Characteristics of
the other models are summarized in the results. All cell
lines were characterized as described earlier [13, 14, 16–23].
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The effect of the nucleoside transport inhibitors nitro-
benzylthioinosine (NBMPR) and dipyridamole on sensitivity
to gemcitabine and CP-4126 were studied in the human
malignant melanoma cells THX and LOX and the human T-
cell leukemia’s MOLT4 and MOLT4/clone8 [22]. These cells
were grown in suspension in RPMI-1640 based growth
medium.
All populations were cultured at 37°C in a humidified
atmosphere of 95% air and 5% CO2 and regularly screened
for Mycoplasma contamination by using a rapid detection
system with a 3H-labelled DNA probe (Gen-Probe, San
Diego, CA, USA) and were found to be negative.
Chemosensitivity tests
Sensitivity to drugs was defined by the concentration of the
drug causing a growth inhibition of 50% (IC50) after 72 h drug
exposure of the cells. Determination of growth inhibition in
the L1210, L4A6, BCLO and Bara-C leukemia cells growing
in suspension was performed by a cell counting method as
previously described [23]. The cells were plated in 24-well
plates in different densities, depending on their doubling
times, to enable log linear growth for 72 h (L5, 50,000 cells/
well; L4A6, 100,000 cells/well; BCLO, 150,000 cells/well;
Bara-C, 175,000 cells/well). Drugs were added directly after
plating the cells. Final concentrations of the drugs in the wells
ranged from 2.10−10 to 10−3M.
For the studies on the effect of nucleoside transport
inhibitors on drug sensitivity, cells were plated at a density
of 2.5.105 cells/ml. The nucleoside transport carrier
inhibitors NBMPR and dipyridamole were used at subtoxic
levels (100 μM and 4 μg/ml, respectively) and gemcitabine
and CP-4126 were added at serial dilutions in the
appropriate concentration range.
All experiments were terminated after 72 h and the
growth rate was determined by cell counting using a
Sysmex Microcell counter. Growth inhibition curves were
made relative to the control of every assay. Two control
values were always included; the number of cells plated at
the day of drug administration (set at 0%) and that of cells
after 72 h not exposed to drugs (set at 100%). Straight lines
connected the points, and the IC50 values were determined
from the interpolated graph.
The determination of the IC50 in the monolayer solid
tumor cells was performed using the SRB assay [24, 25].
On day one 100 μl cell suspension was plated per well in
96 well plates (A2780 6,000 cells/well, AG6000 18,000
cells/well, C26-A 5,000 cells/well, C26-G 8,000 cells/well),
followed by 100 μl of a serial drug dilution at day two. The
final concentrations of the drugs in the wells ranged from
2.10−10 to 2.10−3M. Cells were exposed to the drugs for
72 h, allowing at least two doubling times. After exposure,
cells were precipitated with 50 μl ice-cold 50% w/v TCA
(trichloro acetic acid) and fixed for 60 min after which the
SRB assay was performed as described [26]. Growth
inhibition curves were made by calculation of the relative
growth based on the optical densities of drug-treated and
control wells of every SRB assay. Straight lines connected
the points and the IC50 values were determined from the
interpolated graph [26].
NCI in vitro screen
The cytotoxicity profile of CP-4126 (NSC number 735837)
was also studied in the in vitro screen of the US National
Cancer Institute (NCI). Detailed descriptions of the stan-
dard technical procedures and data analyses performed by
the NCI have been published elsewhere [27, 28] and on
their website http://dtp.nci.nih.gov/index.html. Briefly, the
assay involves plating the cells, preincubation for 24 h,
followed by 48 h continuous drug exposure over a broad
concentration range against a panel of 60 cell lines
comprising nine different tumor types. The cytotoxicity
was assessed with the sulforhodamine B (SRB) protein
assay. Percentage growth is based on optical measurements
and the response parameters 50% growth inhibition (GI50,
corresponding to the IC50 which is used hereafter to avoid
confusion), total growth inhibition (TGI) and 50% lethal
concentration (LC50) are interpolated values representing
the concentrations at which the percentage growth is +50, 0
and −50%, respectively, at the end of the experiments
compared with the start. The LC50 indicates 50% cell kill,
and is used by the NCI as an indication of cytotoxicity.
The results are presented in the form of mean graphs in
which drug effects are calculated as positive or negative
deviations from the average sensitivity of the entire cell
line panel. The COMPARE algorithm of the growth
inhibition (IC50, TGI) and the cytotoxicity (LC50) profile
can be used to obtain an indication of the mechanism of
action of the compound tested (http://dtp.nci.nih.gov/docs/
compare/compare.html).
Deoxycytidine deaminase activity
The effect of the derivatives on purified deoxycytidine
deaminase (dCDA) was determined as described earlier [14,
Fig. 1 a Chemical structure of gemcitabine and the fatty acid
derivative CP-4126. b Mean IC50, TGI and LC50 graphs of CP-4126
on the NCI60 cell lines. Values represent Log values (M). Bars
represent deviations of the means of all tested cell lines. Over all 60
cell lines the average IC50 for CP-4126 was 0.1 μM, the TGI 12.6 μM
and the LC50 70.9 μM. For dFdC the IC50 was 0.2 μM, the TGI
0.9 μM and the LC50 1.0 μM. The dFdC data were obtained from the
NCI60 database (dtp.nci.nih.gov), which also lists the separate disease
specific cell lines. c COMPARE analysis of CP-4126 (NSC 735837)
with standard agents of the NCI database including gemcitabine
(NSC613327). 1 DNA antimetabolite, 2 topoisomerase 1 inhibitor,
3 topoisomerase 2 inhibitor, 4 alkylating agent

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29]. Briefly, enzyme activity was determined at 37°C
with purified enzyme at 500 μM dCyd or gemcitabine as
a substrate and 500 μM the competitive compound
(gemcitabine and CP-4126). A blank without substrate
and inhibitor and a control with a substrate but without
an inhibitor was included in every experiment. After 15
or 25 min incubation precipitation of the proteins by
addition of 40% w/v TCA terminated the reaction. The
supernatant was neutralized with trioctylamine/1,1,2-
trichloro-trifluoroethane (v/v: 4/1). The upper, aqueous
layer containing the substrate dCyd or gemcitabine
and their respective products deoxyuridine or 2′,2′-
difluorodeoxyuridine, was analyzed using reversed phase
HPLC [29].
Animals and xenograft testing
Female BALB/c nude (nu/nu) mice were used, 5–8 weeks
of age at the start of the experiment (20–27 g). The animals
were maintained under specific pathogen-free conditions,
and food and water were supplied ad libitum. Housing and
all procedures involving animals were performed according
to protocols approved by the animal care and use
committee, in compliance with the Norwegian and German
National Committees for Animal Experiments guidelines
on animal welfare. Mice were anaesthetized with 5 mg/10 g
propanidid, given ip before tumor tissue implantation. The
panel of human solid tumor xenografts consisted of a
malignant melanoma (THX), one small cell lung carcinoma
(H-146), one non-small cell lung adenocarcinoma (EKVX),
one osteosarcoma (OHS), one malignant fibrous histiocy-
toma (TAXII-1) one non-classifiable sarcoma (MHMX),
one breast cancer (MA-11), one prostate cancer (CRL-
1435), two pancreas cancer models (PANC-1 and
MiaPaCa-2) and one patient-derived [30] colon cancer
(Co6044). Tumor fragments of about 2×2×2 mm, were
implanted subcutaneously into each flank of female nude
mice. At the start of treatment, the minimum tumor
diameter was 4 mm, equivalent to a volume of 32 mm3. If
a mouse died within 2 weeks after the final drug injection,
it was considered a toxic death, and the animal excluded
from the study. Treatment causing more than median 10%
body weight loss, compared with controls, was considered
not evaluable for antitumor efficacy. Tumor volume was
calculated according to the formula: tumor volume ¼
0:5 length width2. Relative Tumor Volumes (RTVs),
were calculated for each individual tumor by dividing the
tumor volume on day X (Vx) by the tumor volume on day
0 (V0) multiplied by 100%. The tumor volume of a
treatment group was expressed as the median RTV of all
mice of the group. The drug effects were calculated from
growth curves constructed on the basis of median RTVs.
Two different methods of antitumor evaluation were used;
by calculation of the T/C values, i.e. by dividing the RTV
of treated mice by that of control mice X 100%; and by the
Specific Growth Delay Factor (SGD) which was defined
as the mean number of tumor-doubling times gained by
the treatment and was calculated with the formula:
SGD ¼ TDtr  TDconð Þ=TDcon. In this formula TDtr is
the tumor doubling time of treated tumors and TDcon that
of untreated tumors. A T/C% of <25% and a SGD >2 were
considered as active.
Mice were treated both ip and by oral gavage. CP-
4126 was used as a liposomal formulation, similar to that
used in clinical studies. Gemcitabine was also used as
the clinical formulation. Dose finding and scheduling
studies were performed in order to determine the
maximum tolerated dose (MTD) for the test compounds
using ip administration every 3 days for five doses
(q3dx5) in the range of 25–120 mg/kg for CP-4126 and
90–150 mg/kg for gemcitabine, which is also the optimal
schedule for i.p. and i.v. gemcitabine in mice [20, 31].
Similarly, for oral administration of both gemcitabine and
CP-4126 (given by oral gavage), an every 3rd day
schedule (qd 1, 4, 7, 10 and 13) was used. Since a
continuous infusion of gemcitabine was more active then
the every third day schedule [31], and a daily oral
administration might mimic a continuous infusion we also
tested oral CP-4126 at a daily schedule (qd 1–5). Since
weekly administration is common clinical practice [4] we
also tested a weekly (day 1 and 8) schedule. For ip
administration the MTD (weight loss <10%) of CP-4126
was 40 mg/kg and 120 mg/kg for gemcitabine. Dose
finding studies for oral administration are described in the
results. In order to assess bio-availability of CP-4126 two
male beagle dogs received a single dose of intravenous
CP-4126 (4 mg/kg), followed after a wash-out period by a
capsule of CP-4126 at the same dose (30 mg). The weight
of the animals at start was 7.06 and 7.17 kg. Urine was
sampled at intervals of 0–8 h and 8–24 h. Plasma and urine
samples were analyzed for CP-4126 (plasma only), dFdC and
dFdU using LC-MS-MS, essentially as described for CP-4055
[15]. The AUC was calculated using Win-Nonlin profes-
sional version 6. The plasma pharmacokinetics was also
determined on day 1 of a formal toxicology study, with three
or five animals per group.
Statistical analysis
Differences in inhibition of dCDA activity were evaluated
using t-test for unpaired data. The computer program SPSS
(version 7.5, SPSS, Inc., Chicago, IL) was used for
statistical analysis. Statistical analysis of differences in
tumor size between each treated and the control group was
performed with the non-parametric Mann-Whitney U test at
a cut-off level of p<0.05.
460 Invest New Drugs (2011) 29:456–466
Results
Chemosensitivity tests
The growth inhibitory effects of the compounds in the
parental leukemia and solid tumor cells are listed in Table 1.
The gemcitabine derivative CP-4126 was 1.7-fold less
active in the leukemia L5 cells, but 2-fold more active than
gemcitabine in BCLO cells and equally active in the solid
tumor C26-A cells.
The L4A6 cells were less sensitive to the analog compared
to the parent compound and comparable in Bara-C and C26-G
cells. In AG6000 cells the sensitivity was also comparable, in
line with the complete absence of dCK activity in this cell line
[19], indicating the dependency of CP-4126 to be activated
by dCK.
To study the role of membrane transport for gemcitabine
and CP-4126, differences in sensitivity to the drugs in the
presence of nucleoside transport inhibitors were determined. In
Table 1 IC50 values are listed for gemcitabine and CP-4126 in
human cancer cells with or without 100 μM NBMPR or
4 μg/ml dipyridamole. In the THX human malignant
melanoma cells NBMPR and dipyridamole decreased sensi-
tivity to gemcitabine 55- and 115-fold, respectively, while
sensitivity to CP-4126 was only decreased 1.6- and 1.3-fold,
respectively. The largest difference was found in the MOLT4
human T-cell leukemia cells. NBMPR and dipyridamole
decreased sensitivity to gemcitabine 273- and 203-fold,
respectively, while NBMPR decreased sensitivity to CP-
4126 only 1.8-fold and no difference in sensitivity was found
in the presence of dipyridamole. In the other cell lines tested a
comparable pattern was found, suggesting a nucleoside
transporter independent transport over the cell membrane of
the fatty acid derivative CP-4126.
NCI in vitro screen
The cytotoxic activity of CP-4126 (NSC 735837) was
evaluated in duplicate in the NCI in vitro screen. CP-4126
was tested at five concentrations ranging from 10−4 to
10−8M at one-log increments. The results of one assay are
shown in Fig. 1b, the results of the second assay showed
comparable results and are not shown. Leukemia appeared
to be the most sensitive disease type, followed by renal cell
cancer and NSCLC. Target analysis (http://dtp.nci.nih.gov/
mtargets/mt_index.html) for the nucleoside transporter
hENT in the NCI screen for hENT showed a low expression
for renal cancer and NSCLC, while breast cancer and
leukemia showed a high expression of hENT. Together this
indicates no correlation of the cell lines in the NCI screen
between CP-4126 sensitivity (evaluated as IC50 and TGI)
and hENT expression.
A COMPARE analysis of the IC50 profile of CP-4126
against the profiles of 170 compounds in the standard agent
Cell line Nucleoside transport inhibitor IC50 (μM)
gemcitabine CP-4126
L1210/L5 0.0019±0.0006 0.0033±0.0019
L4A6 8.8±3.6 16±6
BCLO 0.0083±0.0009 0.0042±0.0029
Bara-C 12.7±2.2 13.0±2.0
C26-A 0.016±0.004 0.0015±0.0006
C26-G 0.02±0.01 0.03±0.02
A2780 0.0015±0.0006 0.0025±0.0005
AG6000 185±108 91±6
THX 0.0027±0.0007 0.0040±0.0016
+NBMPRa 0.15±0.05 0.0063±0.0051
+Dipyridamoleb 0.31±0.13 0.0053±0.0037
LOX 0.0047±0.0010 0.0077±0.0028
+NBMPR 1.15±0.06 0.027±0.0006
+Dipyridamole 0.61±0.22 0.025±0.001
MOLT4 0.0030±0.0033 0.028±0.0035
+NBMPR 0.82±0.25 0.051±0.033
+Dipyridamole 0.61±0.26 0.021±0.002
MOLT4/C8 0.46±0.12 0.088±0.013
+NBMPR 8.31±1.20 0.12±0.05
+Dipyridamole 7.62±0.59 0.098±0.030
Table 1 Activity of CP-4126 in
gemcitabine sensitive and
resistant cell lines; role of dCK
deficiency and the effect of the
nucleoside transport inhibitors
NBMPR and dipyridamole
on the cytotoxic activity of
gemcitabine and its analog
CP-4126 in different cell lines
L1210: murine leukemia,
BCLO: rat leukemia, C26-A:
murine colon carcinoma,
A2780: human ovarian cancer,
THX: human malignant mela-
noma, LOX: human malignant
melanoma, EKVX: human lung
adenocarcinoma, MOLT4:
human T-cell leukemia,
MOLT4/clone8: human T-cell
leukemia. Values are means in
μM ± SEM of three experiments
a NBMPR in a concentration of
100 μM
bDipyridamole in a concentration
of 4 μg/ml
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NCI database was performed, as well as a COMPARE
analysis to all compounds in the NCI database where
gemcitabine was also included. The correlation coefficient
for CP-4126 was equal for the correlation with gemcitabine
and topotecan, followed by aphidicolin and 3-HP (Fig. 1c).
Mechanistically most compounds in the top ten are DNA
interactors, of which five are DNA antimetabolites like
gemcitabine. The structurally related compounds and
antimetabolites cytarabine and floxuridine are found at the
end of the top ten list.
Effect of fatty acid derivatives on deoxycytidine deaminase
activity
To study the effect of the fatty acid derivative on
deamination of dCyd and gemcitabine, purified dCDA
enzyme was incubated with dCyd (312 pmol/hr/μl enzyme)
or gemcitabine (624 pmol/hr/μl enzyme) as a substrate and
with CP-4126 as the test compound. CP-4126 was not
detectable in the chromatograms using the applied separa-
tion system. Purified dCDA did not catalyze degradation of
CP-4126, since neither the parent nucleoside gemcitabine
nor its deaminated derivative dFdU were detected. This
means that any observed effect of CP-4126 would be a
direct effect on dCDA. When dCyd and gemcitabine were
added simultaneously, only dFdU was found (1,127 pmol/
hr/μl enzyme), demonstrating that gemcitabine is a much
better substrate for dCDA then dCyd. CP-4126 itself
inhibited deamination of dCyd completely (<1) and
deamination of gemcitabine by 47.2%.
Antitumor activity in sc models
Table 2 summarizes the effects of ip administered CP-
4126 in inhibiting the growth of solid tumor xenografts.
The choice of the xenografts was dependent on the
availability of models and therefore they do not com-
pletely overlap with the in vitro models. Furthermore not
all in vitro models were available as in vivo models. In
the EKVX, non-small cell lung cancer xenograft,
gemcitabine and CP-4126 were equally effective, with
T/C values of 3.4% and 2.9%, respectively. In the H-146
small cell lung cancer xenograft gemcitabine and CP-
4126 were not active. Both gemcitabine and CP-4126
were highly active in the MHMX non-classifiable
sarcoma xenograft, but CP-4126 showed the highest
activity with a T/C of 1.1% and a SGD >12.8.
Gemcitabine was inactive in the TAX II-1 fibrous
histiocytoma xenograft, whereas CP-4126 exerted some
activity. In the OHS osteosarcoma xenograft both com-
pounds were inactive. Gemcitabine was the most active
agent against the THX malignant melanoma xenograft
with a T/C of 1.2% and a SGD of >6.25, whereas for
CP-4126 a T/C of 6.8% and a SGD >2.7 were found. In
the MA-11 breast cancer xenograft only gemcitabine
exerted some activity. In the CRL-1435 prostate cancer
xenograft, gemcitabine and CP-4126 were both active
compounds with SGDs of 2.9 and 3.2, respectively. In
the pancreas xenografts MiaPaCa-2 and PANC-1 gemci-
tabine was poorly tolerated with toxic deaths of 7/7 and
4/9, respectively. In the MiaPaCa-2 model CP-4126 was
tolerated with a weight loss of 0.4%, but had no
antitumor activity. In PANC-1 CP-4126 was tolerated
with a weight loss of 4.6% and had high antitumor
activity with a T/C of 12% and SGD of 6.8.
Antitumor activity and toxicity of orally administered
CP-4126 and gemcitabine in the colon cancer xenograft
Co6044 bearing mice are summarized in Table 3 and in
Fig. 2. Toxicity of gemcitabine given orally at similar
doses as the ip administration was highly unpredictable,
and in general very toxic. Hence, no therapeutic efficacy
could be achieved. In contrast, at a weekly schedule of
two doses, CP-4126 at 50 mg/kg was not toxic, but also
not very effective (T/C of 22%), while at 100 mg/kg
toxicity was acceptable with a T/C of 4%. At 150 mg/kg
toxicity was unacceptable with 3/7 deaths. In an every
third day schedule (five doses) acceptable toxicity and
significant antitumor activity was found at doses of 10, 15
and 20 mg CP-4126/kg. At a dose of 40 mg/kg, a T/C of
5% was found with unacceptable toxicity. A dose of
10 mg CP-4126/kg given at a daily schedule (q3dx5)
showed a favorable toxicity and antitumor activity
(Table 3), while a daily dose of 15 mg/kg was highly
toxic (data not shown).
Antitumor activity and toxicity of orally administered
CP-4126 and gemcitabine in the non-small cell lung
cancer xenografts EKVX and MAKSAX are summarized
in Table 3. For EKVX a daily dose of 10 mg/kg CP-4126
was too toxic for evaluation. A schedule of five times
every 3 days (q3dx5) with 15 mg CP-4126/kg did not
produce a large antitumor effect, but had a favorable
toxicity. The dose of 20 mg/kg did increase the antitumor
effect but also the toxicity. For the MAKSAX tumor the
higher dose of 22.5 mg/kg five times every 3 days CP-
4126 caused acceptable toxicity with a good antitumor
effect.
The oral bioavailability of CP-4126 was evaluated in two
dogs. CP-4126 was not detectable in plasma after oral
administration, while it was detectable after i.v. administra-
tion. Levels of dFdCwere higher than after i.v. administration,
but those of dFdU were lower. In line with the latter finding
excretion of dFdU in the urine was higher after i.v. than after
oral administration (Table 4). The half-life of dFdC after iv
administration of CP-4126 to dogs was longer than that after
administration of dFdC to dogs (unpublished data), mice and
humans [5, 31–33].
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Discussion
In this paper we describe the cytotoxic activity and
mechanism of action of the gemcitabine derivative CP-
4126 in a panel of rodent, human leukemia and solid tumor
cell lines and xenografts. The IC50 values of the gemcita-
bine derivative CP-4126 in the solid tumor cells were
similar to those of gemcitabine; however, the derivative was
Treatment Deaths Weight loss (%) Maximal T/C (%)
Schedule (days) Dose (mg/kg)
CP-4126
Co6044 1 and 8 50 0/7 0 22
1 and 8 100 1/7 4 4
1 and 8 150 3/7 10 5
1, 4, 7, 10 and 13 10 0/7 1 35
1, 4, 7, 10 and 13 15 0/7 1 27
1, 4, 7, 10 and 13 20 1/7 3 16
1, 4, 7, 10 and 13 40 2/8 7 5
1 through 5 5 0/7 3 20
1 through 5 10 0/7 5 8
gemcitabine
1, 4 and 7 40 5/7 1 8
1, 4 and 7 20 0/7 0 29
CP-4126
EKVX 1 through 5 10 6/6 NA NA
1, 4, 7, 10 and 13 15 0/7 0 74
1, 4, 7, 10 and 13 20 2/6 10 63
MAKSAX 1, 4, 7, 10 and 13 15 2/7 18 62
1, 4, 7, 10 and 13 22.5 2/7 18 37
Table 3 Antitumor efficacy of
orally administered CP-4126
and gemcitabine in the human
colon cancer xenograft Co6044
and in the non-small cell lung
cancer xenografts EKVX and
MAKSAX
Antitumor effect was expressed
as T/C (treated tumor size/
control tumor size) in %
NA not applicable. Each mouse
carried 1–2 tumors, depending
on the take rate
Tumor Compound Number of tumors Toxicity Antitumor effect
Deaths Mean weight loss (%) T/C (%) SGD
EKVX gemcitabine 9 0/6 0.3 3 3.4
CP-4126 9 0/6 0 7 2.9
H-146 gemcitabine 7 0/6 0.3 59 0.8
CP-4126 7 0/6 0 59 0.3
MHMX gemcitabine 9 2/7 2.1 2 >7.2
CP-4126 9 1/6 0 1 >12.8
TAX II-1 gemcitabine 8 0/6 0 53 0.5
CP-4126 8 0/6 0.7 30 1.3
OHS gemcitabine 14 0/9 0 24 0.8
CP-4126 13 1/9 0 43 0.5
THX gemcitabine 16 0/8 0 1 >6.25
CP-4126 16 0/8 0 7 >2.7
MA-11 gemcitabine 7 2/6 7.7 7 1.8
CP-4126 9 1/6 0 29 0.7
CRL-1435 gemcitabine 7 3/7 6.8 6 2.9
CP-4126 9 3/8 3.0 9 3.2
PANC-1 CP-4126 7 0/6 4.6 12 6.8
MiaPaCa-2 gemcitabine 7 4/9 14.0 32 3.3
CP-4126 14 1/9 0.4 59 0.7
Table 2 Antitumor efficacy of
ip administered gemcitabine and
CP-4126 in various human
xenografts
Mice were treated ip every third
day for five doses at the Maxi-
mum Tolerated Dose. Antitumor
effect was expressed as T/C%
(treated tumor size/control
tumor size) ×100% and SGD
(Specific Growth Delay). A
T/C% <25% and an SGD >2
were considered as active.
Depending on the model 1–2
tumors were implanted in each
mouse in each flank in the
thoracic area. EKVX: non-small
cell lung adenocarcinoma,
H-146: small cell lung cancer,
MHMX: non-classifiable
sarcoma, TAXII-1: malignant
fibrous histiocytoma, OHS:
osteosarcoma, THX:
malignant melanoma, MA-11:
breast cancer, CRL-1435: pros-
tate cancer; PANC-1; MiaPaCa-
2: pancreatic cancer
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more active in BCLO cells. Comparably a cytarabine
derivative acylated at the 4-amino position N4-octadecyl-
1-beta-D-arabinosylcytosine was found to be equally active
as cytarabine in several solid tumor and leukemia cell lines
[34]. Several N4-acyl poly(ethyleneglycol) prodrugs of
cytarabine exhibited superior activity compared to cytar-
abine in a solid lung tumor model [35].
The resistance to cytarabine in L4A6 and Bara-C cells is
related to a decreased dCK activity [23]. In Bara-C cells
cytarabine and gemcitabine resistance was related to a
substrate dependent dCK deficiency. No dCK activity was
found with cytarabine or gemcitabine as a substrate, but a
normal activity with dCyd as a substrate [23]. CP-4126 was
less active in solid tumor cells than the parental drug. In
AG6000 cells, which are highly resistant to gemcitabine as
a result of a dCK deficiency, no difference in sensitivity for
either gemcitabine or CP-4126 was found, clearly confirm-
ing that CP-4126 is, like gemcitabine, also dependent upon
activation by dCK.
Since gemcitabine can be inactivated by deamination
catalyzed by dCDA [5], we tested the effect of CP-4126 on
deamination of dCyd and gemcitabine. Since gemcitabine is
a better substrate CP-4126 inhibited deamination of dCyd
completely and dFdU was formed, indicating competition
for the enzyme [36, 37]. CP-4126 effectively inhibited
deamination of dCyd and gemcitabine. Although theoreti-
cally inhibition of deamination of gemcitabine might result
in higher drug levels and higher cytotoxicity, the role of
dCDA in the development of resistance is not clear [38]. In
vitro dCyd analogs are less effective in systems in which
dCDA has a higher activity e.g. through transfection of the
gene [33], and addition of a dCDA inhibitor increased
activity of cytarabine and gemcitabine. A high dCDA
activity will also affect gemcitabine pharmacokinetics,
while clinically at a low dCDA activity gemcitabine causes
higher toxicity [33, 39]. Since CP-4126 is not a substrate
for dCDA and inhibits gemcitabine deamination a better
bioavailability for gemcitabine derived from CP-4126 can
be expected. In line with this finding the excretion of dFdU
was lower in dogs after oral administration then after i.v.
administration.
Since gemcitabine can be inactivated by deamination
catalyzed by dCDA [5], we tested the effect of CP-4126 on
deamination of dCyd and gemcitabine. Since gemcitabine is
a better substrate CP-4126 inhibited deamination of dCyd
completely and dFdU was formed, indicating competition for
the enzyme [36, 37]. CP-4126 effectively inhibited deami-
nation of dCyd and gemcitabine. Although theoretically
inhibition of deamination of gemcitabine might result in
higher drug levels and higher cytotoxicity, the role of dCDA
in the development of resistance is not clear [38]. In vitro
dCyd analogs are less effective in systems in which dCDA
has a higher activity e.g. through transfection of the gene
[33], and addition of a dCDA inhibitor increased activity of
cytarabine and gemcitabine. A high dCDA activity will also
affect gemcitabine pharmacokinetics, while clinically at
a low dCDA activity gemcitabine causes higher toxicity
[33, 39]. Since CP-4126 is not a substrate for dCDA and
inhibits gemcitabine deamination a better bioavailability for
gemcitabine derived from CP-4126 can be expected. In line
with this finding the excretion of dFdU was lower in dogs
after oral administration then after i.v. administration.
Resistance of C26-G cells was associated with an
increased RRM1 expression [21]. Since inhibitors of
Table 4 Bioavailability of orally administered CP-4126 in two dogs
Compound Dose Plasma AUC Urine excretion
CP-4126 (μM/h) gemcitabine (μM/h) dFdU (μM/h) dFdU (%)
CP-4126 iv 4 mg/kg 3.2, 2.5 14.4, 11.9 65.4, 52.3 64.5, 65.8
CP-4126 oral 4.3 mg/kg 0, 0 21.8, 10.7 55.0, 60.1 55.0, 46.3
The half-life of CP-4126 after iv administration varied between 0.05 and 0.07 h, that of gemcitabine between 1.7 and 3.4 h and that of dFdU
between 10.8 and 11.2 h for doses of CP-4126 varying from 2 to 6 mg/kg
Fig. 2 Antitumor efficacy of CP-4126 as an oral drug in the human
colon cancer xenograft Co6044. Mice treated with saline, qd 1–5 (▲),
100 mg/kg CP-4126, qd 1,7 (●), 20 mg/kg CP-4126. qd 1, 4, 7, 10,
13, (∇) and 10 mg/kg CP-4126, qd 1–5 (□). The curve for the optimal
schedule of gemcitabine (not shown) was in between that of the
control and q3d schedule
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nucleoside carrier transport decreased the sensitivity of
murine and human leukemia cells to cytarabine, but not to
an elaidic acid derivative [13], decreased nucleoside
transport activity might be a mechanism of resistance to
cytarabine. Membrane passage does not seem a limiting
factor in vitro for CP-4126, however, the lipophilicity of
CP-4126 seems an advantage when uptake in the tumor is
limited [40]. Moreover, possibly CP-4126 might act as a
depot form similar to the lipophilic analogs of cytarabine
[13]. Preliminary data confirmed this observation [41]. CP-
4126 showed a similar activity as gemcitabine itself;
however, due to their nature a different administration
schedule might be of advantage. Several clinical studies
show a clear dependence of gemcitabine for an active
transport system: at a low tumoral expression of ENT the
survival of patients with pancreatic cancer was shorter than
in patients with a high expression, measured either by PCR
[42] or immunohistochemistry [43]. For such patients CP-
4126, which bypasses ENT mediated uptake, could be an
active alternative.
Compared to gemcitabine, CP-4126 showed a similar
growth inhibition pattern to published values for gemcita-
bine, with a Pearson correlation coefficient with a similar
degree of correlation with topoisomerase inhibitors and
DNA-antimetabolites. Since the COMPARE correlation
coefficient with gemcitabine was below 0.8, but still quite
high, it probably follows a similar mode of action.
However, additional mechanisms of action can not be
excluded, e.g. the released elaidic acid might have a
separate effect on cells. Further studies concentrated on
the in vivo activity of CP-4126 against xenografts. When
given ip, CP-4126 proved to be equally active or more
active than gemcitabine in human tumors of different
histological origin, but for none of the models a deficiency
of ENT was reported. Moreover, CP-4126 was well
tolerated as an oral drug with an impressive activity
combined with a mild toxicity profile in mice bearing a
colon cancer xenograft. Both activity and toxicity were
dose and schedule dependent, which was in contrast to
gemcitabine, which was highly toxic as an oral drug.
In conclusion, CP-4126 is an interesting gemcitabine
derivative possibly mediating cytotoxicity through trans-
porter independent membrane passage and self-potentiation
by inhibition of degradation of gemcitabine. CP-4126
showed equal antitumor activity to gemcitabine in various
xenograft models. Furthermore, equal antitumor activity
was observed when oral administration was compared to
intraperitoneal administration. It was previously shown that
gemcitabine itself has no activity and it has a variable and
low bioavailability when administered orally in mice [32].
Considering the recent trend to treat patients with variants
of cytostatic agents that can be administered orally (e.g.
Capecitabine, as oral 5-fluorouracil and the development of
oral taxanes), CP-4126 might be a future oral alternative for
gemcitabine.
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